| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
NADA targets multiple receptors and channels. It is a potent endogenous agonist at the TRPV1 channel. It also exhibits agonist activity at the cannabinoid CB1 receptor. Additionally, it targets the anandamide membrane transporter and the anandamide amidohydrolase (fatty acid amide hydrolase, FAAH). It may also interact with novel ligand-gated cation channels in the striatum.
|
|---|---|
| ln Vitro |
In vitro, NADA potently activates TRPV1 channels with an EC50 of ~50 nM. It shows affinity for the cannabinoid CB1 receptor with a Ki of 0.25 µM. It acts as a substrate for FAAH. In striatal preparations, it induces rapid Ca2+ entry and the concomitant release of dopamine and glutamate, suggesting novel presynaptic targets.
|
| ln Vivo |
In vivo, NADA is an endogenous lipid that modulates pain, inflammation, and neurotransmission. It is considered an "endogenous capsaicin-like substance". Its activity at TRPV1 and CB1 receptors suggests it plays a role in nociception, feeding behavior, and other physiological processes.
|
| Enzyme Assay |
Non-cellular assays for NADA typically involve receptor binding studies using membrane preparations from cells expressing TRPV1 or CB1 receptors. Radioligand displacement assays are used to determine binding affinity (Ki values). Its hydrolysis by FAAH can be measured using standard enzymatic assays with radiolabeled substrates.
|
| Cell Assay |
Cellular assays for NADA are conducted using cell lines expressing TRPV1 or CB1 receptors. Intracellular calcium influx, a hallmark of TRPV1 activation, can be measured using fluorescent calcium indicators. CB1 receptor activation can be assessed by measuring inhibition of forskolin-stimulated cAMP accumulation.
|
| Animal Protocol |
In vivo animal experiments for NADA are conducted to study its effects on pain, inflammation, and other physiological processes. It may be administered via intracerebroventricular (ICV) or systemic injection, and its effects on pain-related behaviors, body temperature, or feeding are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of NADA are not well-characterized. As an endogenous lipid, it is rapidly metabolized, likely by enzymes such as FAAH. Its stability in biological fluids is limited. The compound is typically used in research settings and is not developed as a therapeutic.
|
| Toxicity/Toxicokinetics |
Toxicological data for NADA are limited, as it is an endogenous compound and research reagent. Its toxicological profile has not been extensively studied. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
N-acetyldopamine is a secondary amide formed by the condensation of the carboxyl group of acetic acid and the amino group of dopamine. It is a metabolite of dopamine and is found in human urine and marine organisms. N-acetyldopamine belongs to the classes of secondary amides, acetamides, catechols, and N-(fatty acyl)-dopamine compounds, and its function is related to that of dopamine. It has been reported that N-acetyldopamine has been detected in Aedes aegypti, Cryptocoryne, and other organisms with relevant data.
NADA is an important research tool for studying the endocannabinoid and endovanilloid systems. It is also known as N-arachidonoyl dopamine. Its dual activity at TRPV1 and CB1 receptors makes it unique for investigating the crosstalk between these two important signaling pathways. |
| Molecular Formula |
C10H13NO3
|
|---|---|
| Molecular Weight |
195.22
|
| Exact Mass |
195.09
|
| CAS # |
2494-12-4
|
| PubChem CID |
100526
|
| Appearance |
Colorless to light yellow oil
|
| Density |
1.235g/cm3
|
| Boiling Point |
486.7ºC at 760mmHg
|
| Flash Point |
248.1ºC
|
| Vapour Pressure |
4.27E-10mmHg at 25°C
|
| Index of Refraction |
1.578
|
| LogP |
1.167
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
196
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1=C(O)C=CC(CCNC(=O)C)=C1
|
| InChi Key |
OFSAJYZMIPNPHE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H13NO3/c1-7(12)11-5-4-8-2-3-9(13)10(14)6-8/h2-3,6,13-14H,4-5H2,1H3,(H,11,12)
|
| Chemical Name |
N-[2-(3,4-dihydroxyphenyl)ethyl]acetamide
|
| Synonyms |
NADA; N-acetyldopamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (512.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.75 mg/mL (19.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1224 mL | 25.6121 mL | 51.2243 mL | |
| 5 mM | 1.0245 mL | 5.1224 mL | 10.2449 mL | |
| 10 mM | 0.5122 mL | 2.5612 mL | 5.1224 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
